Bydureon

RSS

exenatide

Authorised
This medicine is authorised for use in the European Union.

Overview

Bydureon is a diabetes medicine used together with other diabetes medicines including long-acting insulin to treat adults and children aged 10 years and above with type 2 diabetes whose blood glucose (sugar) levels are not adequately controlled with the other medicines.

Bydureon contains the active substance exenatide.

This EPAR was last updated on 26/08/2022

Authorisation details

Product details
Name
Bydureon
Agency product number
EMEA/H/C/002020
Active substance
exenatide
International non-proprietary name (INN) or common name
exenatide
Therapeutic area (MeSH)
Diabetes Mellitus, Type 2
Anatomical therapeutic chemical (ATC) code
A10BJ01
Publication details
Marketing-authorisation holder
AstraZeneca AB
Revision
23
Date of issue of marketing authorisation valid throughout the European Union
17/06/2011
Contact address
151 85 Södertälje
Sweden

Product information

14/07/2022 Bydureon - EMEA/H/C/002020 - II/0074

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Drugs used in diabetes

Therapeutic indication

Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations).

Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with:

  • Metformin
  • Sulphonylurea
  • Thiazolidinedione
  • Metformin and sulphonylurea
  • Metformin and thiazolidinedione

in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

Assessment history

Changes since initial authorisation of medicine

Related content

How useful was this page?

Add your rating
Average
1 rating
3 ratings